OncoLink Cancer Treatment and Resources
OncoLink Cancer Treatment and Resources

NCI Resources

 
NCI CANCERLIT® Search: Chronic Myelogenous Leukemia - October 2001
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Consistent loss of heterozygosity at 14Q32 in lymphoid blast crisis of chronic myeloid leukemia. Nodal T cell blast crisis in chronic myeloid...
NCI CANCERLIT® Search: Chronic Myelogenous Leukemia - September 2001
Table of ContentsIn vivo purging of peripheral blood stem cells obtained by apheresis, using high-dose chemotherapy and granulocyte colony-stimulating factor in chronic myelogenous leukemia patients.Insertion (22;9)(q11;q34q21) in a patient...
NCI CANCERLIT® Search: Chronic Myelogenous Leukemia - April 2002
Acral sclerosis due to interferon-alpha-2b in chronic myelogenous leukemia. [Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease] NCCN: Chronic myelogenous leukemia. [Successful treatment with...
NCI CANCERLIT® Search: Chronic Myelogenous Leukemia - August 2002
[Study of apoptosis induced by indomethacin in chronic myeloid leukemia] [Graft vs. tumor effect in chronic granulocytic leukemia] [Study of calcitonin gene methylation in chronic myeloid leukemia by using Hpa II-PCR] [Chromosome 8 trisomy...
NCI CANCERLIT® Search: Chronic Myelogenous Leukemia - February 2002
Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell Cytokine expression of T cells in chronic myeloid leukemia. [New molecular therapy options in hematology and...
NCI CANCERLIT® Search: Chronic Myelogenous Leukemia - January 2002
Telomerase activity in patients with chronic myeloid leukemia and lymphoma. Persisting molecular remission ten years after donor lymphocyte infusion for hematologic relapse in chronic myeloid leukemia. New drug targets genetic malfunction...
NCI CANCERLIT® Search: Chronic Myelogenous Leukemia - July 2002
Cultured autografting for juvenile myelomonocytic leukaemia. Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia. [Current pharmacotherapy of chronic myeloid...
NCI CANCERLIT® Search: Chronic Myelogenous Leukemia - June 2002
Unable to resist. Differences among the polyadenylated RNA sequences of human leucocyte populations: an approach to the objective classification of human Cutaneous lesions and chronic myelocytic leukemia (CML) in progression. A case of...
NCI CANCERLIT® Search: Chronic Myelogenous Leukemia - March 2002
Implications of signal transduction inhibition for the treatment of chronic myeloid leukemia. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Interferon-alfa-based treatment of chronic...
NCI CANCERLIT® Search: Chronic Myelogenous Leukemia - May 2002
Imatinib mesylate. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a...
NCI CANCERLIT® Search: Chronic Myelogenous Leukemia - October 2002
Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant Identification of T-cell clones showing expansion associated with graft-vs-leukemia effect on chronic...
NCI CANCERLIT® Search: Chronic Myelogenous Leukemia - September 2002
[Clinical significance of erythrocyte ferritin in refractory anemia and chronic myeloid leukemia] [Molecular cytogenetic monitoring of chimerism and minimal residual disease in patient with chronic myeloid leukemia after allogenic and ...
NCI/PDQ® Health professionals: Chronic Myelogenous Leukemia
TABLE OF CONTENTS General Information Stage Information Treatment Option Overview Chronic Phase Chronic Myelogenous Leukemia Accelerated Phase Chronic Myelogenous Leukemia Blastic Phase Chronic Myelogenous Leukemia Relapsing Chronic...
OncoLink I wish u knew...

Dr. Glatstein shares some of the important lessons he has conveyed upon the many oncology professionals he has trained. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS